⏳ Fetching live dividend data...
Home › Calculator › PHIOW Dividend Calculator 2026
Phio Pharmaceuticals Corp. · NASDAQ
Price: $0.02 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in PHIOW → $254394849589347264.00M in 10 years · $20,956,475,681,210,234,000,000.00/month
Phio Pharmaceuticals Corp., a biotechnology company, develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on silencing tumor-induced suppression of the immune system. The company develops PH-762 which targets the checkpoint protein PD-1 on immune cells for used in adoptive cell transfer (ACT); PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for used in ACT; and PH-790 which targets PD-L1 protein that keeps immune cells from attacking nonharmful cells in the body. It has collaborations with the Gustave Roussy and Medigene AG, as well as with Helmholtz Zentrum München. Phio Pharmaceuticals has collaboration with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open PHIOW position with:
Real after-tax yield depends on where you live and how you hold PHIOW.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 8620.69% | 8617.89% | $862,069 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 7327.59% | 7324.79% | $732,759 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 6896.55% | 6893.75% | $689,655 / yr |
| 🇬🇧 UK ISA | 0% | 8620.69% | 8617.89% | $862,069 / yr |
| 🇬🇧 UK Taxable | 8.75% | 7866.38% | 7863.58% | $786,638 / yr |
| 🇨🇦 TFSA | 0% | 8620.69% | 8617.89% | $862,069 / yr |
| 🇨🇦 CA Taxable | 25% | 6465.52% | 6462.72% | $646,552 / yr |
| 🇦🇺 Super (pension) | 15% | 7327.59% | 7324.79% | $732,759 / yr |
| 🇦🇺 AU Taxable | 30% | 6034.48% | 6031.68% | $603,448 / yr |
| 🇩🇪 DE Taxable | 26.375% | 6346.98% | 6344.18% | $634,698 / yr |
| 🇫🇷 FR Taxable | 30% | 6034.48% | 6031.68% | $603,448 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
PHIOW pays quarterly — 4 times per year. Next ex-div: TBD.
How PHIOW compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for PHIOW sourced from FMP /financial-growth endpoint — real data, not estimates.
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| A-Award | 2026-02-05 | 16,600 | — | — | ||
| A-Award | 2026-02-05 | 16,600 | — | — | ||
| A-Award | 2026-02-05 | 23,800 | — | — | ||
| A-Award | 2026-02-05 | 47,000 | — | — | ||
| A-Award | 2026-02-05 | 18,500 | — | — | ||
| A-Award | 2026-02-05 | 120,000 | — | — | ||
| Buy | 2025-12-31 | 5,000 | $1.03 | $5.2K | ||
| Buy | 2025-12-23 | 5,000 | $1.02 | $5.1K | ||
| Buy | 2025-11-21 | 5,000 | $1.14 | $5.7K | ||
| Buy | 2025-11-18 | 5,000 | $1.27 | $6.3K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the PHIOW dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →